Lexaria Bioscience Corp. (LEXX)
NASDAQ·Healthcare·Biotechnology
$0.89
-6.33%
Mkt Cap $14.10M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q2 2026 Apr 13, 2026 | $50.00K | $20.00K | -60.00% | -$0.10 | -$0.06 | +40.00% | — | — |
| Q1 2026 Jan 13, 2026 | $100.00K | — | — | -$0.13 | -$0.07 | +46.15% | — | — |
| Q4 2025 Nov 26, 2025 | $137.00K | $174.00K | +27.01% | -$0.16 | -$0.13 | +18.75% | — | — |
| Q3 2025 Jul 14, 2025 | $137.00K | $174.00K | +27.01% | -$0.15 | -$0.21 | -40.00% | — | — |
| Q2 2025 Apr 14, 2025 | $91.33K | $174.00K | +90.52% | -$0.16 | -$0.15 | +6.25% | — | — |
| Q1 2025 Jan 10, 2025 | $100.00K | $183.92K | +83.92% | -$0.12 | -$0.16 | -33.33% | — | — |
| Q4 2024 Nov 26, 2024 | $100.00K | $84.00K | -16.00% | -$0.11 | -$0.15 | -36.36% | — | — |
| Q3 2024 Jul 12, 2024 | $150.00K | $84.00K | -44.00% | -$0.10 | -$0.13 | -30.00% | — | — |
| Q2 2024 Apr 9, 2024 | — | $145.00K | — | -$0.10 | -$0.06 | +40.00% | — | — |
| Q1 2024 Jan 12, 2024 | — | $151.28K | — | -$0.11 | -$0.13 | -18.18% | — | — |
| Q4 2023 Nov 21, 2023 | — | -$3.43K | — | -$0.17 | -$0.12 | +29.41% | — | — |
| Q3 2023 Jul 14, 2023 | $170.00K | $93.15K | -45.21% | -$0.25 | -$0.37 | -48.00% | — | — |
| Q2 2023 Apr 14, 2023 | $190.00K | $20.02K | -89.46% | — | -$0.22 | — | — | — |
| Q1 2023 Jan 17, 2023 | — | $101.48K | — | — | -$0.30 | — | — | — |
| Q4 2022 Nov 25, 2022 | $195.00K | $111.15K | -43.00% | -$0.21 | -$0.24 | -14.29% | — | — |
| Q3 2022 Jul 14, 2022 | $120.00K | $99.72K | -16.90% | -$0.28 | -$0.41 | -46.43% | — | — |
| Q2 2022 Apr 11, 2022 | $150.00K | $30.65K | -79.57% | $0.21 | -$0.25 | -219.05% | — | — |
| Q1 2022 Jan 14, 2022 | — | $13.88K | — | — | -$0.35 | — | — | — |
| Q4 2021 Nov 29, 2021 | $31.00K | $31.02K | +0.07% | -$0.23 | -$0.22 | +4.35% | — | — |
| Q3 2021 Jul 15, 2021 | — | $204.06K | — | — | -$0.40 | — | — | — |